GLPBio

Signaling Pathways

Research Area, Signaling Pathways | GlpBio Life Science Products Suppliers

Read More about this category

The antibody-drug conjugate (ADC), a humanized or human monoclonal antibody conjugated with highly cytotoxic small molecules (payloads) through chemical linkers, is a novel therapeutic format and has great potential to make a paradigm shift in cancer chemotherapy. The three components of the ADC together give rise to a powerful oncolytic agent capable of delivering normally intolerable cytotoxins directly to cancer cells, which then internalize and release the cell-destroying drugs. At present, two ADCs, Adcetris and Kadcyla, have received regulatory approval with >40 others in clinical development.

ADCs are administered intravenously in order to prevent the mAb from being destroyed by gastric acids and proteolytic enzymes. The mAb component of the ADC enables it to circulate in the bloodstream until it finds and binds to tumor-specific cell surface antigens present on target cancer cells. Linker chemistry is an important determinant of the safety, specificity, potency and activity of ADCs. Linkers are designed to be stable in the blood stream (to conform to the increased circulation time of mAbs) and labile at the cancer site to allow rapid release of the cytotoxic drug. First generation ADCs made use of early cytotoxins such as the anthracycline, doxorubicin or the anti-metabolite/antifolate agent, methotrexate. Current cytotoxins have far greater potency and can be divided into three main groups: auristatins, maytansines and calicheamicins.

The development of site-specific conjugation methodologies for constructing homogeneous ADCs is an especially promising path to improving ADC design, which will open the way for novel cancer therapeutics.

References:

[1] Tsuchikama K, et al. Protein Cell. 2016 Oct 14. DOI:10.1007/s13238-016-0323-0.

[2] Peters C, et al. Biosci Rep. 2015 Jun 12;35(4). pii: e00225. doi: 10.1042/BSR20150089.

Research Areas

Products Related to Signaling Pathways(40876)

  • GC79702 structure
    GC79702DSPE-PEG2000-CTP
    Purity: >95.00%

    DSPE-PEG2000-CTP is a PEG compound which composed of DSPE and a Cardiac-targeting peptide CTP.

  • GC79703 structure
    GC79703DSPE-PEG1000-GNYTCEVTELTREGETIIELK
    Purity: >98.00%

    DSPE-PEG1000-GNYTCEVTELTREGETIIELK is a PEG compound which composed of DSPE and a peptide mimicking the function of CD47 (GNYTCEVTELTREGETIIELK).

  • GC79704 structure
    GC79704DPPE-PEG2000-Mal
    Purity: >98.00%

    DPPE-PEG2000-Mal is a conjugate composed of DPPE, PEG chains, and maleimide (Mal).

  • GC79705 structure
    GC79705DMG-PEG2000-Mal-Cys-penetratin
    Purity: >95.00%

    DMG-PEG2000-Mal-Cys-penetratin is a conjugate composed of dimyristoylglycerol (DMG), a PEG chain, and terminal maleimide (Mal).

  • GC79706 structure
    GC797065-LOX-IN-9
    CAS: 2668-47-5
    Purity: >98.00%

    5-LOX-IN-9 is a 5-lipoxygenase and cyclooxygenase inhibitor, with an IC 50 of 0.2 pM against guinea pig 5-LOX and an IC 50 of 0.7 pM against bovine COX.

  • GC79707 structure
    GC79707ST1072
    CAS: 1402703-50-7
    Purity: >98.00%

    ST1072 is an inhibitor of CerS4 and CerS6.

  • GC79708 structure
    GC79708Alcudacigib TFA
    Purity: >99.00%

    Alcudacigib (ASP1570; DGKζ-IN-1) TFA is an orally active diacylglycerol kinase ζ ( DGKζ ) inhibitor, with an IC 50 of 4.7 nM against human DGKζ and an IC 50 of 3.0 nM against mouse DGKζ. Alcudacigib TFA selectively inhibits the kinase activity of DGKζ and induces proteasome-dependent degradation of DGKζ protein.

  • GC79709 structure
    GC79709HK2-IN-4
    CAS: 2748366-80-3
    Purity: >99.50%

    HK2-IN-4 is a selective hexokinase 2 ( HK2 ) inhibitor with an IC 50 value of 0.79 μM and a K d value of 0.41 μM.

  • GC79710 structure
    GC79710ATX-012
    CAS: 1777792-44-5
    Purity: >98.00%

    ATX-012 is an ionizable cationic lipid for the assembly of mRNA -delivering lipid nanoparticles (LNPs).

  • GC79711 structure
    GC79711PENAO TFA
    Purity: >95.50%

    PENAO TFA is the trifluoroacetic acid of PENAO.

  • GC79712 structure
    GC79712Mitochondrial-targeted peptide BP29 acetate
    Purity: >98.00%

    Mitochondrial-targeted peptide BP29 acetate is a mitochondria-targeted iron chelator linked to a mitochondria-homing SS-peptide.

  • GC79713 structure
    GC79713D-Ribonic acid ammonium
    CAS: 90801-23-3
    Purity: >98.00%

    D-Ribonic acid ammonium is a metabolite of D-Ribose.

  • GC79714 structure
    GC79714MMP-9-IN-13
    CAS: 3085676-77-0
    Purity: >98.00%

    MMP-9-IN-13 (Example 1) is a selective inhibitor of human MMP9 with an IC 50 value of 0.02 nM.

  • GC79715 structure
    GC79715C-telopeptide acetate
    Purity: >98.00%

    C-telopeptide acetate is a cross-linked peptide of type I collagen that is released during bone resorption and correlates with bone mineral density (BMD).

  • GC79716 structure
    GC79716Dnp-PLGLWAr-NH2 acetate
    Purity: >98.50%

    Dnp-PLGLWAr-NH2 acetate is a synthetic collagenase/gelatinase substrate.

  • GC79717 structure
    GC79717BT1769 acetate
    Purity: >98.00%

    BT1769 acetate is a conjugate and antitumor agent targeting MT1-MMP, with a K d value of 3.35 nM against human targets.

  • GC79718 structure
    GC79718NCATS-SM7270
    Purity: >99.00%

    NCATS-SM7270 is a highly specific NOX2 inhibitor, with an IC 50 of 4.09 μM.

  • GC79719 structure
    GC79719Gibberellin A34
    CAS: 32630-92-5
    Purity: >98.00%

    Gibberellin A34 is a Hypoxanthine guanine phosphoribosyltransferase 1 ( HPRT1 ) inhibitor that can be isolated from immature seeds of Calonyction aculeatum.

  • GC79720 structure
    GC79720Nampt-IN-20
    CAS: 1362150-16-0
    Purity: >95.50%

    Nampt-IN-20 is a nicotinamide phosphoribosyltransferase ( Nampt ) inhibitor with a IC 50 of 9.0 nM.

  • GC79721 structure
    GC79721Substance P, free acid TFA
    Purity: >98.00%

    Substance P, Free Acid TFA is a native substance P analog, but shows no biological activity of substance P [1] .

  • GC79722 structure
    GC79722Escholtzine perchlorate
    CAS: 77790-29-5
    Purity: >98.00%

    Escholtzine perchlorate is an Alkaloid.

  • GC79723 structure
    GC79723Alofropodect
    CAS: 1829530-11-1
    Purity: >98.00%

    Alofropodect is an orally active, blood-brain barrier permeable phosphodiesterase 10A ( PDE10A ) inhibitor with IC 50 values of 1 nM (Reference 1) and 35 nM (Reference 2).

  • GC79724 structure
    GC79724CHI3L1-IN-5
    CAS: 2249043-42-1
    Purity: >98.50%

    CHI3L1-IN-5 (Compound Z17) is a highly selective CHI3L1 inhibitor with a K D value of 6 μM.

  • GC79725 structure
    GC79725DI-1548
    CAS: 2247060-97-3
    Purity: >98.00%

    DI-1548 is a potent, selective, and irreversible covalent inhibitor of DCN1 ( IC 50 = 4.6 nM).